|
Canada-0-PASTA Directorios de empresas
|
Noticias de la compañía :
- Cipla Therapeutics and SIGA Technologies Announce Strategic Partnership . . .
With our drug development expertise under the animal rule and government contracting expertise, and Cipla’s novel antibiotic products and extensive manufacturing capabilities, we are confident that together we are ideally-suited to provide innovative solutions to BARDA and other government customers ”
- Orchid Pharma Launch New Antibiotic with Cipla | Angel One
Orchid Pharma Limited announced in a stock exchange filing the launch of its new drug, Cefepime-Enmetazobactam, approved for treating complicated urinary tract infections (cUTI), hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP)
- Meningitis drugs in development, 2024 - Pharmaceutical Technology
The Meningitis drugs in development market research report provides comprehensive information on the therapeutics under development for Meningitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type
- Cipla Therapeutics and SIGA Technologies Announce Strategic Partnership . . .
With our drug development expertise under the animal rule and government contracting expertise, and Cipla's novel antibiotic products and extensive manufacturing capabilities, we are
- Cipla Ltd: About Cipla Pharma, Company Profile, Products . . . - IBEF
Cipla launched Cipremi, an experimental anti-viral drug remdesivir, having Emergency Use Authorisation (EUA) treatment for adult and paediatric patients hospitalized with suspected or laboratory confirmed COVID-19 infection
- Orchid Pharma partners with Cipla to launch new antibiotic in India
Orchid Pharma Limited recently announced the launch of its new drug – Cefepime-Enmetazobactam, which has been approved for the treatment of complicated Urinary Tract infections (cUTI),
- Cipla launches novel injectable for drug resistant Urinary Tract Infections
CUTI Treatment: Cipla has launched Zemdri, a novel injectable treatment for complicated Urinary Tract Infections (cUTIs) in India, targeting drug-resistant strains with promising clinical trial data
- Orchid Pharma join hands with Cipla to launch new antibiotic in India
Chennai-based Orchid Pharma, the only Indian pharmaceutical company to have ever invented a New Chemical Entity (NCE), on Friday announced the launch of its new drug - Cefepime-Enmetazobactam, which has been approved for the treatment of complicated urinary tract infections (cUTI), hospital-acquired pneumonia (HAP), and ventilator-associated
- Cipla - API | Innovative high class drugs producer
Our API pipeline consists of 75+ complex developments in the therapy areas of Oncology, Hep C, ARV, Diabetology, CVS, CNS, Respiratory etc Technologies such as process analytical technology, continuous flow reactors for process development among others are used in the API development process
- Meningitis drugs - likelihood of approval - Pharmaceutical Technology
Meningitis is an indication for drug development with over 20 pipeline drugs currently active According to GlobalData, preregistered drugs for Meningitis have a 100% likelihood of approval (LoA) indication benchmark
|
|